This Article Abstract Full Text (PDF) All Versions of this Article: 110/9/1140    most recent 01.CIR.0000139851.50067.E4v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muzaffar, S. Articles by Jeremy, J. Y. Search for Related Content PubMed PubMed Citation Articles by Muzaffar, S. Articles by Jeremy, J. Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID NITRIC OXIDE Related Collections Pathophysiology Pulmonary circulation and disease Oxidant stress Endothelium/vascular type/nitric oxide

(Circulation. 2004;110:1140-1147.)
© 2004 American Heart Association, Inc.

Original Articles

Nitroaspirins and Morpholinosydnonimine but Not Aspirin Inhibit the Formation of Superoxide and the Expression of gp91^phox Induced by Endotoxin and Cytokines in Pig Pulmonary Artery Vascular Smooth Muscle Cells and Endothelial Cells

Saima Muzaffar, PhD; Nilima Shukla, PhD; Gianni Angelini, FRCS; Jamie Y. Jeremy, PhD

From the Bristol Heart Institute, University of Bristol, Bristol, UK.

Correspondence to Dr Jamie Y. Jeremy, Department of Cardiac Surgery, Bristol Royal Infirmary, Bristol BS2 8HW, UK. E-mail j.y.jeremy{at}bris.ac.uk

Received May 1, 2003; de novo received December 16, 2003; revision received March 18, 2004; accepted March 24, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Although nonsteroidal antiinflammatory drugs (NSAIDs) are ineffective in treating acute respiratory distress syndrome (ARDS), inhalational NO has proved to be useful. NO-donating NSAIDs may therefore be more effective in treating ARDS than NSAIDs alone. Because oxidant stress is central to the pathophysiology of ARDS, the effect of nitroaspirins (NCX 4016, NCX 4040, and NCX 4050) compared with morpholinosydnonimine (SIN-1; an NO donor) and aspirin (ASA) on superoxide (O₂^·–) formation and gp91^phox (an active catalytic subunit of NADPH oxidase) expression in pig pulmonary artery vascular smooth muscle cells (PAVSMCs) and endothelial cells (PAECs) was investigated.

Methods and Results— Cultured PAVSMCs and PAECs were incubated with lipopolysaccharide (LPS), tumor necrosis factor (TNF)-, and interleukin (IL)-1 (with or without NO-ASA, SIN-1, or ASA) for 16 hours, and O₂^·– release was measured by use of the reduction of ferricytochrome c. The expression of gp91^phox was assessed by use of Western blotting. LPS, TNF-, and IL-1 all stimulated the formation of O₂^·– and expression of gp91^phox in both PAVSMCs and PAECs, an effect inhibited by NADPH oxidase inhibitors, diphenyleneiodonium, and apocynin. SIN-1, NCX 4016, and NCX 4050 but not ASA alone inhibited the formation of O₂^·– and expression of gp91^phox.

Conclusions— LPS and cytokines promote the formation of O₂^·– in PAVSMCs and PAECs through an augmentation of NADPH oxidase activity, which in turn is prevented by NO. Thus, NO may play a protective role in preventing excess O₂^·– formation, but its negation by O₂^·– may augment the progress of ARDS. The inhibitory effect of nitroaspirins suggests that they may be therapeutically useful in treating ARDS through the suppression of NADPH oxidase upregulation and O₂^·– formation.

Key Words: superoxides • NADPH oxidase • nitric oxide • respiratory distress syndrome, adult • pulmonary artery

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Oxidative stress plays a central role in the pathogenesis of acute respiratory distress syndrome (ARDS),¹ a condition characterized by a time-dependent worsening of intrapulmonary inflammation and hypertension.^1–3 Principal among the reactive oxygen species (ROS) generated by oxidative stress is superoxide (O₂^·–), which reacts with nitric oxide (NO) to produce peroxynitrite (ONOO^·–), thereby reducing bioavailable NO.⁴ A reduction of NO availability promotes not only vasoconstriction but also the adhesion of leukocytes and platelets, which in turn release a battery of vasoconstrictors and cytokines,^1,4 thereby exacerbating ongoing inflammatory cascades and the development of pulmonary hypertension. Adherent neutrophils and monocytes release tumor necrosis factor- (TNF-) and interleukins (ILs), the blood levels of which are markedly elevated in patients with ARDS.⁵ In turn, TNF- and ILs and lipopolysaccharide (LPS) upregulate enzymes that generate O₂^·– in cultured vascular tissues, in particular, NADPH oxidase.^6,7 A self-perpetuating inflammatory cascade ensues.

ARDS is a difficult, if not intractable, condition to treat.⁸ Because inflammation is the pathological hallmark of ARDS,⁹ it would be reasonable to expect that nonsteroidal antiinflammatory drugs (NSAIDs) would be effective in treating ARDS. However, NSAIDs, in particular ibuprofen, have proved ineffective in reducing mortality associated with ARDS despite eliciting a profound inhibition of proinflammatory eicosanoids, such as thromboxane A₂ and prostaglandin E₂.⁹ Because NSAIDs also inhibit the formation of prostacyclin (PGI₂)⁹ and inhaled PGI₂ has also proved effective in treating ARDS,¹⁰ it is possible that NSAIDs may be intrinsically "self-defeating" in this particular scenario. Notably, we have recently demonstrated that PGI₂ inhibits the formation of O₂^·– via a downregulation of NADPH oxidase activity induced by cytokines and endotoxin in pulmonary arterial cells.¹¹ NSAIDs would therefore remove this protective system, thereby augmenting oxidative stress and the depletion of NO as described above. In this context, inhaled NO has proved more effective in treating ARDS and reducing leukocyte activity and oxidant stress in ARDS.¹² NO acts at multiple sites to limit inflammation, including the inhibition of leukocyte and platelet adhesion and of release substances, including that of cytokines.¹³ Because NO and PGI₂ have similar properties, including vasodilatation, the inhibition of adhesion molecule expression, inhibition of platelet and leukocyte activity, and a reduction in oxidative stress,^13,14 it is reasonable to suggest that NO may also inhibit NADPH oxidase expression.

A novel class of NSAIDs that may be effective in treating ARDS is the NO-donating aspirins (NO-ASA). NO-ASA releases NO in vivo while retaining the antiinflammatory capacity of aspirin.¹⁵ The donation of NO may also compensate for the inhibition of PGI₂ by NSAIDs. Indeed, drugs of this class have proved effective in preventing gastropathy associated with aspirin by virtue of their NO-donating capacity.¹⁵ The NO moiety of NO-ASA may also act by preventing excess O₂^·– formation, which, as proposed above, would be of potential therapeutic benefit in treating ARDS. To test these proposals, the effect of the NO-ASA adducts NCX 4016, NCX 4040, and NCX 4050 compared with an NO donor alone (morpholinosydnonimine, SIN-1) and ASA alone on O₂^·– formation and gp91^phox (a catalytic subunit of NADPH oxidase) in response to cytokines and endotoxin in pig pulmonary artery vascular smooth muscle cells and endothelial cells was investigated.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Dissection of Pulmonary Arteries
Lungs were obtained from White Landrace male pigs of body weight ranging from 20 to 35 kg. All animal experiments were conducted in accordance with the rules and regulations of Bristol University and the Home Office for the care and use of experimental animals. Pigs were anesthetized with an intravenous injection of ketamine hydrochloride (10 mg/kg; Ketaset Injection, Fort Dodge Animal Health) and inhaled oxygenated halothane. The internal carotid artery was exposed, a cannula was placed in the carotid artery, and the animals were then exsanguinated. The chest was opened by median sternotomy, and the lungs were then excised from the chest. Pulmonary arteries (PAs) of 3- to 4-mm diameter were dissected from the lungs within 30 minutes and placed in DMEM with glutamax-1 (DMEM; GibcoBRL).

Culture of Pulmonary Artery Vascular Smooth Muscle Cells and Endothelial Cells
Pulmonary artery vascular smooth muscle cells (PAVSMCs) and endothelial cells (PAECs) were prepared according to previously published methods.^16,17 PAECs were grown in endothelial cell growth medium (PromoCell) at 37°C in a 95% air–5% CO₂ incubator (Heraeus, Hera Cell, Kandro Laboratory Products). PAVSMCs were maintained in DMEM (supplemented with 10% FCS, 100 U/mL penicillin, and 100 µg/mL streptomycin) at 37°C in a 95% air–5% CO₂ incubator. Subconfluent cultures of pulmonary VSMCs were growth arrested by washing in sterile PBS (GibcoBRL) and incubating in quiescing medium (serum-free DMEM supplemented with 0.5% lactalbumin hydrolysate, 100 U/mL penicillin, and 100 µg/mL streptomycin) for 72 hours. Cultured cells were then incubated in fresh serum-free medium supplemented with the factor(s) under investigation.

Studies on the Source of O₂^·– Formation Elicited by Endotoxin and Cytokines
PAVSMCs and PAECs were incubated with LPS (1 µg/mL; Escherichia coli; 026:B6; Sigma Chemical Co), human recombinant IL-1 (10 ng/mL; R&D Systems) or human recombinant TNF- (10 ng/mL); R&D Systems) at 37°C in a 95% air–5% CO₂ incubator. The measurement of O₂^·– released by cells was performed by detection of ferricytochrome c reduction.⁷ Thus, after incubation for 16 hours, pulmonary arterial cells were rinsed 3 times in PBS to remove drugs and stimulators and preequilibrated in DMEM without phenol red for 10 minutes at 37°C in a 95% air–5% CO₂ incubator. Then 20 µmol/L horseradish cytochrome c (Sigma Chemical Co) with or without 500 U/mL copper-zinc superoxide dismutase (SOD; Sigma Chemical Co) was added to the segments or cells and incubated at 37°C in a 95% air–5% CO₂ incubator for 1 hour. The reaction medium was then removed, and the maximum rate of reduction of cytochrome c was determined at 550 nm by use of a temperature-controlled Anthos Lucy 1 spectrometer (Laboratory-tech International and converted to nanomoles of O₂^·– by use of E_{550 nm}=21.1 mmol · L^–1 · cm^–1 as the extinction coefficient for (reduced-oxidized) cytochrome c. The reduction of cytochrome c that was inhibitable with SOD reflected actual O₂^·– release. Segments were blotted, dried, and weighed, data being expressed as nmol of O₂^·– · mg tissue^–1 · h^–1. Cells were rinsed in PBS and lysed with 0.1% vol/vol Triton-X100, and total protein content was measured by use of a BCA-protein assay kit (Pierce). Data are expressed as µmol O₂^·– · mg protein^–1 · h^–1.

To determine the source of the O₂^·–, PAECs and PAVSMCs were preincubated with diphenyleneiodonium chloride (DPI; 10 µmol/L) or apocynin (1 µmol/L; NADPH oxidase inhibitors; Sigma Chemical Co), rotenone (10 µmol/L; an inhibitor of mitochondrial respiration; Sigma Chemical Co), and allopurinol (100 µmol/L; an inhibitor of xanthine oxidase; Sigma Chemical Co) for 2 hours before the measurement of O₂^·–.

Effect of Nitroaspirins, SIN-1, and Aspirin on O₂^·– Formation and gp91^phox Expression
The NO-ASA adducts studied were NCX 4040 (2-acetoxybenzoate 2-(2-nitroxy)-butyl ester), NCX 4050 (2-acetoxybenzoate 2-(2-nitroxy-methyl)-phenyl ester, and NCX 4016 ((2-acetyloxy)benzoic acid 6-(nitrooxymethyl)-2-pyridinylmethyl ester chloride), which were supplied by NiCox SA. PAVSMCs or PAECs were incubated with LPS (1 µg/mL), IL-1 (10 ng/mL), or TNF- (10 ng/mL) in either the absence or the presence of (1) nitroaspirins: NCX 4016, NCX 4040, and NCX 4050 (all 0 to 10 µmol/L), (2) 3-morpholinosydnonimine hydrochloride (SIN-1; 0 to 10 µmol/L; Sigma Chemical Co), and (3) aspirin (0 to 10 µmol/L; Sigma Chemical Co) for 16 hours. O₂^·– formation was measured by ferricytochrome c assay as described above.

For Western analysis, the medium was removed after 16-hour incubation and the cells lysed with Tris buffer (50 mmol/L, pH 7.4) containing 1% vol/vol Triton X-100, EDTA (10 mmol/L) PMSF (1 mmol/L), pepstatin (0.05 mmol/L), and leupeptin (0.2 mmol/L). Extracts were boiled at a 1:1 ratio with Tris (50 mmol/L, pH 6.8, containing 4% wt/vol sodium dodecyl sulfate, 10% vol/vol glycerol, 4% vol/vol 2-mercaptoethanol, and 2 mg/mL bromophenol blue). Samples of equal protein (100 µg) were loaded onto 12% Tris-glycine SDS gels and separated by electrophoresis. After transfer to nitrocellulose, the blots were primed with a specific human anti-neutrophil gp91^phox antibody (2.5 µg/mL final concentration) raised in mouse (a kind gift from Professor D. Roos, CLB, Amsterdam, the Netherlands). The blots were then incubated with goat anti-mouse immunoglobulin (Dako) conjugated to horseradish peroxidase (1:1000 dilution) and developed by enhanced chemiluminescence (Amersham International). Rainbow markers (14 to 220 kDa; Amersham) were used for molecular weight determination.

Effects of Guanylyl Cyclase Inhibition With Oxadiazoloquinoxalinone on O₂^·– Release
To determine whether the effects of nitroaspirins and SIN-1 on O₂^·– formation were mediated by the NO-cGMP axis, PAECs and PAVSMCs were incubated with various concentrations of the guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ)¹⁸ over a 16-hour incubation with LPS, IL-1, or TNF- (with or without nitroaspirins, SIN-1, or aspirin). The production of O₂^·– was measured by ferricytochrome c assay, as described above.

Effect of Nitroaspirins, SIN-1, and Aspirin on the Direct Quenching of O₂^·–
Although in preceding experiments, cells were washed free of drugs, their direct effects on O₂^·– levels (quenching) was studied by use of a xanthine/xanthine oxidase system in the absence of cells. Nitroaspirins, aspirin, and SIN-1 (all 0 to 10 µmol/L) were incubated with a xanthine (100 µmol/L)/xanthine oxidase (0.15 U/mL) mixture (Sigma Chemical Co), which generates a steady flux of superoxide radicals,¹¹ and assayed for O₂^·– formation by use of conditions identical to those described above.

Effect of Drugs on PGI₂ Formation
As mentioned in the introduction, the nitroaspirins possess the potential to compensate for the intrinsic negative effect of aspirin on PGI₂ formation. To confirm that nitroaspirins inhibit PGI₂ formation, PAVSMCs were seeded in 12-well plates, grown to confluence, and incubated for 16 hours with various concentrations of the nitroaspirin, aspirin, or SIN-1. After incubation, cells were washed with PBS, and PGI₂ formation was stimulated with calcium ionophore A23187 (10 µmol/L; Sigma).¹¹ After incubation for 30 minutes at 37°C, supernatants were removed and aliquots taken for the measurement of PGI₂ (as 6-keto-PGF₁; R&D Systems) by use of enzyme-linked immunoassay kits.¹¹

Statistical Analysis
Statistical analysis was performed by use of Instat (GraphPad Software Inc). Before the study was undertaken, power analysis was performed, from which it was determined that a number of n=6 was required for statistical assurance. Thus, data are expressed as mean±SEM, n=6. Statistical analysis was performed by use of 1-way ANOVA or post hoc unpaired, 2-sided Student’s t test with a Bonferroni adjustment. Statistical significance was assumed at a value of P<0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Source of O₂^·– Formation Elicited by LPS, IL-1, and TNF- by PAECs and PAVSMCs
LPS (1 µg/mL) and TNF- and IL-1 (both at 10 ng/mL) augmented O₂^·– release from PAECs and PAVSMCs after a 16-hour time course (Figure 1). DPI and apocynin, both inhibitors of NADPH oxidase (but not rotenone or allopurinol) significantly inhibited O₂^·– formation and release from PAECs and PAVSMCs after a 16-hour incubation with LPS, IL-1, and TNF- (Figure 1).

View larger version (25K): [in this window] [in a new window]   Figure 1. Effect of DPI (10 µmol/L), apocynin (1 µmol/L), rotenone (10 µmol/L), and allopurinol (100 µmol/L) on formation of superoxide (O2·–) by porcine PAECs and PAVSMCs in response to (A) LPS (1 µg/mL), (B) IL-1 (10 ng/mL), and (C) TNF- (10 ng/mL) after a 16-hour incubation. Each point indicates mean±SEM, n=6. *P<0.01, LPS/cytokine-stimulated values vs controls. $P<0.01, drug effects vs LPS/cytokine-stimulated values.

Effect of Nitroaspirins, NO Donor (SIN-1), Aspirin, and Guanylyl Cyclase Inhibitor (ODQ) on O₂^·– Release and gp91^phox Expression
The nitroaspirins (NCX 4016, NCX 4040, or NCX 4050) and SIN-1 but not aspirin alone inhibited LPS- and cytokine-induced O₂^·– release (Figures 2 and 3). In both cell types, the maximum inhibition by nitroaspirins and SIN-1 was achieved at 0.1 µmol/L, which was reversed by the addition of NO-sensitive guanylyl cyclase inhibitor, ODQ, in a dose-dependent manner (Figure 4), indicating that the cGMP-protein kinase G axis mediates this inhibitory effect of NO. Furthermore, nitroaspirins (NCX 4016 and NCX 4050) and SIN-1 also inhibited any increase in LPS-, IL-1–, and TNF-–induced gp91^phox protein expression in PAVSMCs (Figure 5) and PAECs (Figure 6). Aspirin alone, however, had no significant effect on LPS- or cytokine-induced gp91^phox expression in both cell types (Figures 5 and 6).

View larger version (17K): [in this window] [in a new window]   Figure 2. Effect of nitroaspirins NCX 4016, NCX 4040, NCX 4050, SIN-1 alone, and aspirin alone on (A) LPS- (1 µg/mL), (B) IL-1– (10 ng/mL), and (C) TNF- (10 ng/mL)–induced SOD-inhibitable superoxide (O2·–) formation by PAECs after a 16-hour incubation. Each point indicates mean±SEM, n=6. $P<0.01, zero (0) vs basal level. *P<0.01, significantly inhibited vs LPS- or cytokine-treated (0) cells.

View larger version (17K): [in this window] [in a new window]   Figure 3. Effect of nitroaspirins NCX 4016, NCX 4040, NCX 4050, SIN-1 alone and aspirin alone on (A) LPS- (1 µg/mL), (B) IL-1– (10 ng/mL), and (C) TNF- (10 ng/mL)–induced SOD-inhibitable superoxide (O2·–) formation by PAVSMCs after a 16-hour incubation. Each point indicates mean±SEM, n=6. $P<0.01, zero (0) vs basal level. *P<0.01, significantly inhibited vs LPS- or cytokine-treated cells.

View larger version (32K): [in this window] [in a new window]   Figure 4. Effect of ODQ on inhibition of O2·– release from PAECs and PAVSMCs by nitroaspirin (NCX 4016, NCX 4040, and NCX 4050; all 100 nmol/L) after a 16-hour incubation with (A) LPS (1 µg/mL), (B) IL-1 (10 ng/mL) and (C) TNF- (10 ng/mL). Each point indicates mean±SEM, n=6. *P<0.05, nitroaspirin-treated vs LPS- or cytokine-treated cells only. $P<0.05, significantly increased vs nitroaspirin-treated cells.

View larger version (39K): [in this window] [in a new window]   Figure 5. Western analysis of NAD(P)H oxidase in PAVSMCs by use of a monoclonal antibody directed against gp91phox-subunit of human neutrophil NAD(P)H oxidase (MoAb 48). Cells were either not treated or treated with (A) LPS (1 µg/mL), (B) IL-1 (10 ng/mL), or (C) TNF- (10 ng/mL) for 16 hours with one of the following: NCX 4016 (100 nmol/L), NCX 4050 (100 nmol/L), SIN-1 (1 µmol/L), or aspirin (10 µmol/L). Bands detected are 91 kDa for heavily glycosylated form of gp91phox and 66 kDa for less glycosylated form of gp91phox. Bottom, Representative blots and top, results of densitometric analyses of 6 blots (expressed as relative optical density [O.D.]/mm2). Pig neutrophil lysates were used as positive controls. *P<0.05, significantly inhibited vs LPS- or cytokine-treated cells.

View larger version (40K): [in this window] [in a new window]   Figure 6. Protein expression of NAD(P)H oxidase in PAECs as measured by Western blot using a monoclonal antibody directed against gp91phox-subunit of human neutrophil NAD(P)H oxidase (MoAb 48). Cells were either not treated or treated with (A) LPS (1 µg/mL), (B) IL-1 (10 ng/mL), or (C) TNF- (10 ng/mL) for 16 hours with one of the following: NCX 4016 (100 nmol/L), NCX 4050 (100 nmol/L), SIN-1 (1 µmol/L), or aspirin (10 µmol/L). Bands detected are 91 kDa for heavily glycosylated form of gp91phox and 66 kDa for less glycosylated form of gp91phox. Top, Representative blots and bottom, results of densitometric analyses of 6 blots (expressed as relative optical density [O.D.]/mm2). Pig neutrophil lysates were used as positive controls. *P<0.05, significantly inhibited vs LPS- or cytokine-treated cells.

Effect of Nitroaspirins, SIN-1, and Aspirin on Quenching of O₂^·– and PGI₂ Formation
The nitroaspirins, aspirin, and SIN-1 had no significant quenching effect on O₂^·– generated by the xanthine/xanthine oxidase system (Table, top). Nitroaspirins and aspirin all inhibited the formation of PGI₂ (as 6-keto-PGF₁) in a dose-dependent manner (Table, bottom). In contrast, SIN-1 alone significantly elevated the PGI₂ levels produced by PAVSMCs (Table, bottom).

View this table: [in this window] [in a new window]   Effect of Nitroaspirins, SIN-1, and Aspirin on Xanthine/Xanthine Oxidase–Generated O2·– Formation and PGI2 Production by PAVSMCs

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The present study demonstrates, first, that TNF-, IL-1, and LPS promote the formation of O₂^·– in both PAVSMCs and PAECs in a time-dependent manner and at concentrations that have been reported to appear in the blood of patients with ARDS.¹⁹ Furthermore, apocynin and DPI, both inhibitors of NADPH oxidase activity, completely inhibited the generation of O₂^·– in response to TNF-, IL-1, and LPS, indicating that increased NADPH oxidase activity/levels mediate these effects, a conclusion confirmed by the upregulation of gp91^phox by TNF-, IL-1, and LPS. These data consolidate the proposition that the pathogenic effect of endotoxins and cytokines in ARDS may be mediated, in part, through an induction of intrapulmonary arterial oxidative stress.^1,7

In a previous study, we demonstrated that the enhancement of O₂^·– formation in intact pig pulmonary arteries by TNF-, IL-1, and LPS resulted in the formation of peroxynitrite (ONOO^·–)⁷ by the reaction between O₂^·– and NO.⁴ The lowering of NO bioavailability may result in vasoconstriction and pulmonary hypertension as well as a local increase in cytokines, because NO is a vasodilator²⁰ and prevents the adhesion of platelets and neutrophils.²⁰ ONOO^·– itself may be proinflammatory in this scenario, because it promotes adhesion molecule expression in leukocytes²¹ and inhibits PGI₂ synthase activity.²² In addition, in the present study, the NO donor SIN-1 inhibited gp91^phox expression and O₂^·– formation through a guanylyl cyclase–dependent pathway, because the effects were reversed by ODQ. This effect could not be ascribed to a direct quenching effect, because the drugs were washed from of the system before O₂^·– or gp91^phox expression was measured, and the nitroaspirins and SIN-1 had no effect on O₂^·– generated by xanthine/xanthine oxidase in the absence of cells. Thus, endogenous NO formation may protect the pulmonary vasculature by preventing the expression of NADPH oxidase induced by LPS and cytokines. The converse is that the loss of NO availability by the overproduction of O₂^·– would render the vasculature susceptible to augmented NADPH oxidase activity and therefore to increased NO destruction, thereby worsening the inflammatory cascades associated with ARDS.

In terms of treating ARDS, inhalational NO has been shown to be beneficial.¹² In the present study, not only SIN-1 but also the NO-donating aspirins inhibited O₂^·– formation and NADPH oxidase upregulation, again via a cGMP-dependent mechanism. In contrast, aspirin had no effect, indicating that the effects of the nitroaspirins are mediated by the NO rather than the aspirin moiety of the drug. Several studies have demonstrated that nitroaspirins exert both NO-mediated effects and the inhibition of cyclooxygenase and therefore of the generation of proinflammatory eicosanoids,¹⁵ such as thromboxane A₂ (TXA₂) and PGE₂.

Although many clinical trials have demonstrated that NSAIDS are relatively ineffective in treating ARDS,⁹ they have been shown to inhibit the formation of proinflammatory eicosanoids in patients with sepsis.⁹ One possible explanation for the lack of efficacy of NSAIDs in ARDS is that they also inhibit the formation of the antiinflammatory eicosanoid PGI₂.¹⁴ The possible importance of endogenous PGI₂ in protecting against ARDS is exemplified by the therapeutic benefits of inhalational PGI₂ to treat the condition.¹⁰ In a recent study, we also demonstrated that the PGI₂ analogue iloprost inhibits the expression of NADPH oxidase and O₂^·– formation in pig PAVSMCs and PAECs, again induced by LPS and cytokines.¹¹ Thus, NSAIDs may intrinsically negate their therapeutic potential through this "double-edged" effect on PGI₂. In the present study, the nitroaspirins inhibited PGI₂ formation but still blocked the gp91^phox expression and O₂^·– formation. Thus, the NO-donating aspirins, by virtue of possessing an NO-donating moiety, may overcome this limitation of NSAIDs, because NO has properties similar to those of PGI₂, including vasodilation and the inhibition of adhesion molecule expression and platelet and leukocyte activity.^13,20

Notwithstanding NO and the lack of effect of ASA on NADPH oxidase activity, the aspirin moiety of NO-ASA may reduce vascular O₂^·– formation through an indirect effect on platelet TXA₂ formation. We found that the TXA₂ analogue U46619 promoted O₂^·– formation and NADPH oxidase expression in pig PAECs and PAVSMCs.¹¹ Because hyperactive platelets and increased TXA₂ formation is a hallmark of ARDS,²³ this inhibition may also be beneficial in attenuating oxidative stress and reducing the prohypertensive actions of TXA₂.¹⁴

One potential drawback of orally administered nitroaspirins, however, is their possible contraindication in sepsis, which etiologically accounts for 40% of ARDS patients.²³ In contrast to the pulmonary hypertension seen in ARDS, sepsis is associated with systemic hypotension, which is evoked by endotoxin-induced inducible NO synthase expression²⁴ and as such may be worsened by an NO donor. Indeed, it has been widely advocated that sepsis can be treated with inhibitors of NO synthase.²⁴ Nevertheless, in the remainder of patients with non–sepsis-mediated ARDS, nitroaspirins may still be appropriate.

In conclusion, this study demonstrates that LPS and cytokines promote the formation of O₂^·– in pig pulmonary arterial cells via an upregulation of NADPH oxidase activity. This would lead to the negation of NO availability and the generation of ONOO^·–, which may render the vasculature susceptible to oxidative attack. The administration of nitroaspirins may be therapeutically useful in treating ARDS through (1) inhibition of leukocyte and platelet adhesion, (2) inhibition of release of cytokines from these blood cells, (3) suppression of NADPH oxidase upregulation and therefore O₂^·– release, (4) replacement of NO depleted by excess O₂^·– formation, and (5) inhibition of TXA₂ formation, a promoter of both oxidative stress and vasoconstriction. Apart from ARDS, these data indicate that the therapeutic action of NO donors, including nitroaspirins, may be mediated, in part, through the suppression of NADPH oxidase expression and therefore excess O₂^·– formation. Nitroaspirins may also be effective in treating vascular diseases associated with oxidative stress.

	Acknowledgments

 
This research was funded by the British Heart Foundation (grant number FS/2001041).

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Chabot F, Mitchell JA, Gutteridge JM, et al. Reactive oxygen species in acute lung injury. Eur Respir J. 1998; 11: 745–757.[Abstract]
   
2. Weinacker AB, Vaszar LT. Acute respiratory distress syndrome: physiology and new management strategies. Annu Rev Med. 2001; 52: 221–237.[CrossRef][Medline] [Order article via Infotrieve]
   
3. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000; 342: 1334–1349.[Free Full Text]
   
4. Stuart-Smith K, Jeremy JY. Microvessel damage in acute respiratory distress syndrome: the answer may not be NO. Br J Anaesth. 2001; 87: 272–279.[Abstract/Free Full Text]
   
5. Pittet J-F, Mackersie RC, Martin TR, et al. Biological markers of acute lung injury: prognostic and pathogenetic significance (state of art). Am J Respir Care Med. 1997; 155: 1187–1205.[Medline] [Order article via Infotrieve]
   
6. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86: 494–501.[Abstract/Free Full Text]
   
7. Muzaffar S, Jeremy JY, Angelini GD, et al. The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax. 2003; 58: 598–604.[Abstract/Free Full Text]
   
8. Brower RG, Ware LB, Berthiaume Y, et al. Treatment of ARDS. Chest. 2001; 120: 1347–1367.[Abstract/Free Full Text]
   
9. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med. 1997; 336: 912–918.[Abstract/Free Full Text]
   
10. Lowson SM. Inhaled alternatives to nitric oxide. Anesthesiology. 2002; 96: 1504–1513.[CrossRef][Medline] [Order article via Infotrieve]
    
11. Muzaffar S, Shukla N, Lobo C, et al. Iloprost inhibits NADPH oxidase expression and superoxide release in porcine pulmonary arteries and cells stimulated with thromboxane A₂, isoprostane F₂ and cytokines. Br J Pharmacol. 2004; 141: 488–496.[CrossRef][Medline] [Order article via Infotrieve]
    
12. Klinger JR. Inhaled nitric oxide in ARDS. Crit Care Clin. 2002; 18: 45–68.[CrossRef][Medline] [Order article via Infotrieve]
    
13. Jeremy JY, Rowe D, Emsley AM, et al. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res. 1999; 43: 580–594.[Free Full Text]
    
14. Jeremy JY, Mehta D, Bryan AJ, et al. Platelets and saphenous vein graft failure following coronary artery bypass surgery. Platelets. 1997; 8: 295–309.[CrossRef][Medline] [Order article via Infotrieve]
    
15. Del Soldato P, Sorrentino R, Pinto A. NO-aspirins: a class of new anti-inflammatory and anti-thrombotic agents. Trends Pharmacol Sci. 1999; 20: 319–323.[CrossRef][Medline] [Order article via Infotrieve]
    
16. Southgate KM, Davies M, Booth RF, et al. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992; 288: 93–99.[Medline] [Order article via Infotrieve]
    
17. Meyrick BO, Ryan US, Brigham KL. Direct effects of E coli endotoxin on structure and permeability of pulmonary endothelial monolayers and the endothelial layer of intimal explants. Am J Pathol. 1986; 122: 140–151.[Abstract]
    
18. Brown AS, Moro MA, Masse JM, et al. Nitric oxide–dependent and independent effects on human platelets treated with peroxynitrite. Cardiovasc Res. 1998; 40: 380–388.[Abstract/Free Full Text]
    
19. Bauer TT, Monton C, Torres A, et al. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax. 2000; 55: 46–52.[Abstract/Free Full Text]
    
20. Ignarro LJ. Physiology and pathophysiology of nitric oxide. Kidney Int. 1996; 55: 2–5.
    
21. Zouki C, Zhang SL, Chan JS, et al. Peroxynitrite induces integrin-dependent adhesion of human neutrophils to endothelial cells via activation of the Raf-1/MEK/Erk pathway. FASEB J. 2001; 15: 25–27.[Free Full Text]
    
22. Zou MH, Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett. 1996; 382: 101–104.[CrossRef][Medline] [Order article via Infotrieve]
    
23. Reines HD, Halushka PV, Cook JA, et al. Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet. 1982; 2: 174–175.[Medline] [Order article via Infotrieve]
    
24. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991; 338: 1557–1558.[CrossRef][Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				S. Wan, N. Shukla, G. D. Angelini, A. P.C. Yim, J. L. Johnson, and J. Y. Jeremy Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: A comparison with aspirin and morpholinosydnonimine (SIN-1). J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 1033 - 1039. [Abstract] [Full Text] [PDF]

				C. E. Teixeira, F. B. M. Priviero, and R. C. Webb Effects of 5-Cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on Smooth Muscle Tone, Soluble Guanylyl Cyclase Activity, and NADPH Oxidase Activity/Expression in Corpus Cavernosum from Wild-Type, Neuronal, and Endothelial Nitric-Oxide Synthase Null Mice J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1093 - 1102. [Abstract] [Full Text] [PDF]

				S. Selemidis, G. J. Dusting, H. Peshavariya, B. K. Kemp-Harper, and G. R. Drummond Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells Cardiovasc Res, July 15, 2007; 75(2): 349 - 358. [Abstract] [Full Text] [PDF]

				X. Fu, D. G. Beer, J. Behar, J. Wands, D. Lambeth, and W. Cao cAMP-response Element-binding Protein Mediates Acid-induced NADPH Oxidase NOX5-S Expression in Barrett Esophageal Adenocarcinoma Cells J. Biol. Chem., July 21, 2006; 281(29): 20368 - 20382. [Abstract] [Full Text] [PDF]

				S Muzaffar, N Shukla, G D Angelini, and J Y Jeremy Acute hypoxia simultaneously induces the expression of gp91phox and endothelial nitric oxide synthase in the porcine pulmonary artery Thorax, April 1, 2005; 60(4): 305 - 313. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 110/9/1140    most recent 01.CIR.0000139851.50067.E4v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muzaffar, S. Articles by Jeremy, J. Y. Search for Related Content PubMed PubMed Citation Articles by Muzaffar, S. Articles by Jeremy, J. Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID NITRIC OXIDE Related Collections Pathophysiology Pulmonary circulation and disease Oxidant stress Endothelium/vascular type/nitric oxide